A multiple-ascending dose study of RG-012 for the trearmet of Alport syndrome
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2018
Price : $35 *
At a glance
- Drugs Lademirsen (Primary)
- Indications Hereditary nephritis
- Focus Adverse reactions
- 06 Nov 2018 Status changed from active, no longer recruiting to completed, according to a Regulus Therapeutics media release.
- 12 May 2017 Accordign to a Regulus (10 Q SEC filings http://files.shareholder.com/downloads/AMDA-14LKIJ/4455726230x0xS1628280-17-4992/1505512/filing.pdf) media release, this study was initiated in the 2016.
- 12 May 2017 New trial record